Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy

Background Septal myectomy is the gold standard treatment for hypertrophic obstructive cardiomyopathy. This study aimed to evaluate the results from patients with hypertrophic cardiomyopathy who had undergone septal myectomy. Methods Data were analysed that has been prospectively collected over 7 years from 345 patients with hypertrophic cardiomyopathy who underwent septal myectomy at Meshalkin National Medical Research Center. Results Six (6) patients (1.7%) died within 30 days of surgery. The mean (standard deviation, SD) resting left ventricular outflow tract gradients reduced from 83.4 (24.2) mmHg preoperatively to 16.2 (8.5) mmHg at discharge (p < 0.001). Of the 345 patients, 329 (95.4%) attended the most recent follow-up assessments, and of these, 254 (77.2%) were categorised as New York Heart Association (NYHA) class I, 64 (19.5%) class II, and 11 (3.3%) class III. The mean overall long-term survival rate after septal myectomy was 95.7% (SD 1.7%) (95% CI, 90.0-97.9). This did not differ from the age -matched and gender -matched general population (log -rank, p = 0.109). At the last follow-up assessments, six of 67 patients who had undergone concomitant Cox -Maze IV procedures had late atrial tachyarrhythmia recurrences. A preoperative short -axis view of left atrial diameter of 57.5 mm (hazard ratio, 1.30 (95% CI, 1.03-1.65), p < 0.001) predicted late atrial tachyarrhythmias (p < 0.002). Conclusions At this hypertrophic cardiomyopathy centre, septal myectomy is associated with low operative and early mortality rates ( <2%), a low risk of early adverse events, and acceptable intermediate -term clinical and haemodynamic results.